A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.

NCT07176728

Status	RECRUITING
Phase	Phase 1
Sponsor	Bayer
Enrollment	16 participants

Key Eligibility Criteria

Inclusion (7)

- Participant must be 18 to 55 years of age inclusive.
- Participants who are overtly healthy Japanese as determined by medical evaluation.
- Body mass index (BMI) within the range 18 - 29.9 kg/m² (inclusive).
- Male participants must agree to use specified contraception during the study and for at least 90 days plus 5 half-lives after.
- Female participants must be a Woman of Nonchildbearing Potential (WONCBP).

... and 2 more (see full listing online)

Exclusion (14)

- Any medical disorder, condition, or history that would impair participation.
- Known hypersensitivity to the study drug or its excipients.
- Known disorders with increased bleeding risk or known congenital/acquired coagulation disorders.
- Use of prescription drugs, over-the-counter drugs, or herbal products within 14 days or 5 half-lives before the study.
- Clinically relevant findings in the ECG, such as a QTcF over 450 msec.

... and 9 more (see full listing online)

Locations (2 total)

SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Fukuoka Pref, Japan
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan